Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan versus valsartan in HFpEF patients on maintenance dialysis
ChiCTR2400092130Phase 4Completed
- Sponsor
- Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) and end-stage kidney disease (ESKD) (2 arms), sponsored by Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoints: Improvement in NYHA functional class, Left ventricular ejection fraction (LVEF) and 1 more. Started Jul 2022; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2400092130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092130.